These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 16176415

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
    Stratta RJ, Alloway RR, Hodge E, Lo A, Pancreas Investigators Vital Outcomes Trial (PIVOT) Study Group.
    Clin Transplant; 2002 Feb; 16(1):60-8. PubMed ID: 11982617
    [Abstract] [Full Text] [Related]

  • 4. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids.
    Otero A, Varo E, de Urbina JO, Martín-Vivaldi R, Cuervas-Mons V, González-Pinto I, Rimola A, Bernardos A, Otero S, Maldonado J, Herrero JI, Barrao E, Domínguez-Granados R.
    Liver Transpl; 2009 Nov; 15(11):1542-52. PubMed ID: 19877219
    [Abstract] [Full Text] [Related]

  • 5. [Daclizumab in combination with mycophenolate mofetil and a late introduction of Tacrolimus at low doses, as a therapeutic approach in the elderly renal transplant donor-recipients pairs in kidney transplant].
    Gentil MA, Osuna A, Capdevilla L, Cantarell C, Pereira P, Mazuecos A, González Molina M.
    Nefrologia; 2008 Nov; 28(3):287-92. PubMed ID: 18590495
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial.
    Abramowicz D, Vanrenterghem Y, Squifflet JP, Kuypers D, Mourad M, Meurisse M, Wissing M.
    Clin Transplant; 2005 Aug; 19(4):475-82. PubMed ID: 16008591
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation.
    Sarwal MM, Yorgin PD, Alexander S, Millan MT, Belson A, Belanger N, Granucci L, Major C, Costaglio C, Sanchez J, Orlandi P, Salvatierra O.
    Transplantation; 2001 Jul 15; 72(1):13-21. PubMed ID: 11468528
    [Abstract] [Full Text] [Related]

  • 14. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
    Montini G, Murer L, Ghio L, Pietrobon B, Ginevri F, Ferraresso M, Cardillo M, Scalamogna M, Perfumo F, Edefonti A, Zanon GF, Zacchello G.
    Transpl Int; 2005 Jan 15; 18(1):36-42. PubMed ID: 15612981
    [Abstract] [Full Text] [Related]

  • 15. The use of daclizumab, tacrolimus and mycophenolate mofetil in african-american and Hispanic first renal transplant recipients.
    Ciancio G, Burke GW, Suzart K, Mattiazzi A, Vaidya A, Roth D, Kupin W, Rosen A, Johnson N, Miller J.
    Am J Transplant; 2003 Aug 15; 3(8):1010-6. PubMed ID: 12859538
    [Abstract] [Full Text] [Related]

  • 16. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients.
    Kuypers DR, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y.
    Clin Transplant; 2003 Jun 15; 17(3):234-41. PubMed ID: 12780674
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts.
    Figueras J, Prieto M, Bernardos A, Rimola A, Suárez F, de Urbina JO, Cuervas-Mons V, Mata Mde L.
    Transpl Int; 2006 Aug 15; 19(8):641-8. PubMed ID: 16827681
    [Abstract] [Full Text] [Related]

  • 19. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study.
    Klintmalm GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola C, Eckhoff DE, Netto GJ, Katz E.
    Liver Transpl; 2007 Nov 15; 13(11):1521-31. PubMed ID: 17969201
    [Abstract] [Full Text] [Related]

  • 20. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.
    Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP.
    Liver Transpl; 2005 Jan 15; 11(1):61-7. PubMed ID: 15690537
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.